Center for Cancer Immunology Research
Directors: Patrick Hwu, M.D., and Larry Kwak, M.D., Ph.D.
The CCIR addresses immunology-based approaches to the treatment of cancer and has emerged as a one-of-a-kind research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurrence.
Unlike targeted therapy and conventional chemotherapy for most malignancies, immunotherapy has the advantage of providing long-term clinical benefit in some patients. Although this benefit has not been seen in all patients treated with immunotherapy, one of the goals of the CCIR is to improve our understanding of the immune system, especially in the context of the tumor immune microenvironment, in order to modulate immunity to optimally enhance patient outcome.
Since the center's inception in 2003, CCIR investigators have made remarkable progress in the number of high-quality publications, level of research support, and number of investigator-initiated pre-clinical studies/clinical trials.
To learn more about the CCIR, we invite you to read our recent Annual Report (Fiscal Year 2013); please click on the image below to open a PDF version of the report.
- Cancer immunotherapy leader Allison to receive 2014 Szent-Gyorgyi Prize
- MD Anderson Announces Collaboration with Johnson & Johnson Innovation on cancer immunotherapy
- MD Anderson teams up with Pfizer to advance cancer immunotherapy
- Science names cancer immunotherapy its 2013 Breakthrough of the Year
- SU2C/CRI supports Dream Team efforts in translational immunology research
Dr. Mark Davis with winners of the
2014 CCIR Poster Session